是GLP-1R激动剂长期寻求的治疗肥胖的灵丹妙药吗?
Georgina K C Dowsett1, Giles S H Yeo1
1MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 0QQ, UK.
Trends in molecular medicine
|July 17, 2023
概括
葡萄糖类1 (GLP-1) 受体激动剂是有效的肥胖治疗方法. 本综述解释了它们的减肥机制以及对超重和肥胖个体的治疗重要性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 葡萄糖类1 (GLP-1) 受体激活剂最初是针对2型糖尿病 (T2D) 的.
- 这些药物在促进超重或肥胖个体减肥方面表现出显著的有效性.
- 它们对体重管理的影响背后的精确机制需要彻底解释.
研究的目的:
- 阐明GLP-1受体激动剂对减肥的作用机制.
- 讨论GLP-1受体激动剂作为治疗肥胖的治疗选择的重要性.
主要方法:
- 关于GLP-1受体激动剂及其对体重的影响研究的文献综述.
- 分析与肥胖治疗相关的药理作用和临床结果.
主要成果:
- GLP-1受体激动剂通过各种途径诱导体重减轻,包括抑制食欲和增加腹感.
- 这些药物在临床试验中显示了体重的大幅减少.
- 它们的有效性超出了血糖控制范围,具有显著的代谢益处.
结论:
- GLP-1受体激动剂代表了肥胖药物治疗的关键进步.
- 了解它们的机制是优化它们在管理超重和肥胖方面的使用的关键.
- 这些疗法为日益增长的全球健康挑战提供了有希望的长期解决方案.
相关概念视频
Glucagon-like Receptor Agonists
364
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
364
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Oral Hypoglycemic Agents: Glinides
189
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
189
Oral Hypoglycemic Agents: Biguanides and Glitazones
236
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
236
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
Regulation of Food Intake
288
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
288


